CTNM Stock — Contineum Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease.

Source: 10-K FY2025 via SEC EDGAR

Share price

$10.67

Market cap

$418.9M

Cash

$244.5M

Enterprise value

$174.4M

Balance sheet

Cash	$244.5M
Debt	$0.0M
Net cash	$244.5M
Enterprise value	$174.4M
Basic shares	23.1M shares
Fully diluted shares	45.9M shares
Fully diluted market cap	$489.6M
Cash per share	$10.58
Quarterly burn	$11.5M
Cash runway	21.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

37.6M

Pre-funded warrants

0.0M

Options

7.7M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.6M

FDSO

45.9M

Cap table as of 2026-06-30.

Price history

Loading CTNM daily closes…

Loading price history…

Next catalyst

PIPE-791 · Jun 12 - Jul 24 in 19 mo · Phase 2 · Idiopathic Pulmonary Fibrosis

Recently reported

JNJ-5120/PIPE-307 Phase 2 Negative · 2026-09-14

MOONLIGHT-1 · major depressive disorder

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24 in 19 mo	PIPE-791	Phase 2	Idiopathic Pulmonary Fibrosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PIPE-791

Phase 2 · Active Modality: small molecule (oral, brain-penetrant)

Target LPAR1

Partnerships Wholly-owned; Company retains worldwide rights to LPAR1 programs

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 2)
Chronic pain (chronic osteoarthritic pain / chronic low back pain) (Phase 1)

Status note LPAR1 inhibitor. PROPEL-IPF global Phase 2 dosing initiated Q1 2026. Phase 1b PET trial completed September 2025; Phase 1b in chronic pain completed April 2026.

PIPE-307

Phase 2 · Active Modality: small molecule (oral)

Aliases JNJ-89495120

Target M1R (muscarinic type 1 receptor)

Partnerships Janssen Pharmaceutica NV (Johnson & Johnson): exclusive worldwide license for development, manufacture and commercialization (February 2023); J&J leads development; Company has opt-in right to co-fund Phase 3 development

Indications

Major depressive disorder (MDD) (Phase 2)
Relapsing-remitting multiple sclerosis (RRMS) (Phase 2)

Status note M1R inhibitor; renamed JNJ-89495120 by J&J. MOONLIGHT-1 Phase 2 in MDD missed its primary endpoint (MADRS change from baseline at Day 5 vs placebo), reported September 14, 2026; J&J evaluating the full data including prespecified exploratory endpoints to inform next steps. VISTA Phase 2 in RRMS completed 2025 without benefit.

CTX-343

Stage not disclosed · Active

Target LPA1R

Partnerships not disclosed

Indications

not disclosed (Stage not disclosed)

Status note Strategic decision to defer further clinical development until funding obtained.

Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PIPE-791 Dose A
Lead indication	Idiopathic Pulmonary Fibrosis
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07284459	Phase 2	Recruiting	Sponsor	CTNM	—	Idiopathic Pulmonary Fibrosis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Contineum Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	1,255,592	no change	0.32%	2026-08-14
Great Point Partners	921,481	+121,283	3.56%	2026-08-14
Ikarian Capital	807,874	no change	2.17%	2026-08-14
Boxer Capital	494,000	no change	0.61%	2026-08-14
ADAR1 Capital Management	278,961	+2,300	0.21%	2026-08-14
Sphera Biotech	183,475	+10,000	0.43%	2026-08-14
Casdin Capital	148,333	no change	0.12%	2026-08-14
Baker Bros. Advisors	0	-1,420,838	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CTNM — Contineum Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CTNM — Contineum Therapeutics Inc.